MRS Brain Imaging for Normal Brain Function
Recruiting in Palo Alto (17 mi)
+1 other location
Overseen byLi An, Ph.D.
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: National Institute of Mental Health (NIMH)
Must not be taking: Anticholinergics, Benzodiazepines, Fluoxetine, others
Disqualifiers: Axis 1 diagnosis, HIV, Neurological illness, Diabetes, others
No Placebo Group
Approved in 1 Jurisdiction
Trial Summary
What is the purpose of this trial?This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of \[13\]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).
Will I have to stop taking my current medications?
If you are taking prescription psychotropic medications (like anticholinergics, benzodiazepines, fluoxetine, antipsychotics, or anticonvulsants), you need to be off them for at least 8 weeks before joining the study.
What data supports the effectiveness of the treatment 3T and 7T device, 3 Tesla device, 7 Tesla device, Magnetic Resonance Spectroscopy (MRS) device, MRS, Magnetic Resonance Spectroscopy, MR Spectroscopy, Proton MRS for normal brain function?
Research shows that using higher magnetic fields like 3T in brain proton spectroscopy improves the clarity and detail of brain scans, helping to better identify and understand various brain conditions. This suggests that the treatment could be effective in providing detailed insights into normal brain function.
12345Is MRS brain imaging safe for humans?
Proton magnetic resonance spectroscopy (MRS) is a noninvasive technique used to analyze brain tissue and is generally considered safe for humans. It is often used alongside MRI to provide additional metabolic information and has been applied in various clinical settings without significant safety concerns.
46789How is MRS treatment different from other treatments for normal brain function?
MRS (Magnetic Resonance Spectroscopy) is unique because it is a noninvasive technique that analyzes the chemical composition of brain tissue, providing detailed metabolic information that other imaging methods cannot. Unlike traditional imaging, MRS can differentiate between normal and abnormal brain tissue by mapping metabolite concentrations, making it particularly useful for understanding brain function and disorders.
3451011Eligibility Criteria
This trial is for healthy adults aged 18-65 who can consent to participate. They must be enrolled in specific protocols, have no serious medical conditions, not use certain psychotropic drugs or substances, and cannot be pregnant or breastfeeding. People with metal implants affected by MRI or claustrophobia are also excluded.Inclusion Criteria
I am generally healthy according to my doctor's evaluation.
Enrolled in Protocol 01-M-0254 or Protocol 17-M-0181
Able to give written informed consent
+1 more
Exclusion Criteria
Positive HIV test
NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.
Clinically significant laboratory abnormalities
+8 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive either oral administration of [13C]glucose or an intravenous infusion of [13C]glucose and/or [13C]acetate while undergoing MRS to measure neurotransmitter metabolism
2 hours
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Participant Groups
The study uses advanced MRS technology at different strengths (3T and 7T) to track how the brain processes glucose into neurotransmitters like glutamate and GABA. It's a non-invasive way to understand brain metabolism in healthy individuals.
1Treatment groups
Experimental Treatment
Group I: One armExperimental Treatment1 Intervention
Subjects receive the same test
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, MD
National Institutes of Health Clinical CenterBethesda, MD
Loading ...
Who Is Running the Clinical Trial?
National Institute of Mental Health (NIMH)Lead Sponsor
References
Comparison of 1.5T and 3T 1H MR spectroscopy for human brain tumors. [2018]We wanted to estimate the practical improvements of 3T proton MR spectroscopy ((1)H MRS) as compared with 1.5T (1)H MRS for the evaluation of human brain tumors.
Brain (1)H-MR spectroscopy in clinical neuroimaging at 3T. [2019]After more than 10 years of use, clinical neuroimaging spectroscopy has proven to be invaluable in the MRI assessment of several brain diseases. The metabolic characterization of diverse brain lesions and pathological conditions is well established by spectroscopy studies at 1.5 T, but recently, an increase in the number of 3T magnets has noticeably improved routine neuroimaging in general. For brain proton spectroscopy, the use of higher magnetic fields has been promising in terms of increasing the signal/noise ratio across the spectrum and widening the frequency bandwidth to allow clearer separation of peaks that are otherwise too close to each other at 1.5 T, especially glutamate, glutamine and gamma-aminobutyric acid (GABA). The individual detection and quantification of these metabolites will add more details to the characterization of brain diseases, and allow the inclusion of more brain pathologies. Moreover, the ongoing advances in dedicated hardware and integrated software have led to more accurate and automated postprocessing, offering neuroradiologists a more user-friendly interface. This is an up to date review of the main clinical applications of brain proton MR spectroscopy that are potentially improved at 3T, taking into account the peculiarities of higher magnetic fields. It is based on both the literature and our own clinical experience, starting from July 2005 and including more than 250 scans at 3T (unpublished material), and emphasizes, for every indication, a practical approach to brain MRS to achieve the optimal clinical impact.
Recent advances in magnetic resonance neurospectroscopy. [2020]Over the past two decades, proton magnetic resonance spectroscopy (proton MRS) of the brain has made the transition from research tool to a clinically useful modality. In this review, we first describe the localization methods currently used in MRS studies of the brain and discuss the technical and practical factors that determine the applicability of the methods to particular clinical studies. We also describe each of the resonances detected by localized solvent-suppressed proton MRS of the brain and discuss the metabolic and biochemical information that can be derived from an analysis of their concentrations. We discuss spectral quantitation and summarize the reproducibility of both single-voxel and multivoxel methods at 1.5 and 3-4 T. We have selected three clinical neurologic applications in which there has been a consensus as to the diagnostic value of MRS and summarize the information relevant to clinical applications. Finally, we speculate about some of the potential technical developments, either in progress or in the future, that may lead to improvements in the performance of proton MRS.
[Can proton magnetic resonance spectroscopy be of any value as a prognostic factor in medulloblastoma?]. [2019]Proton MR spectroscopy (MRS) is a noninvasive chemical analysis of metabolites in brain tissue. Metabolite ratios are useful because age dependant normal values are known and differ significantly from the values obtained in various diseases of brain tissues.
Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. [2015]The basic principles of proton MR spectroscopy as well as newer and more advanced related techniques are reviewed. Spectroscopy is capable of differentiating normal from pathologic brain and provides tissue specificity greater than that of imaging in many instances. Spectroscopic mapping allows for the visualization of the concentration of different metabolites and their distribution within a lesion. This article emphasizes the utility of proton MR spectroscopy in the diagnosis of brain tumors, postradiation therapy changes, infections, degenerative brain disorders, hepatic encephalopathy, ischemia, and demyelination.
Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. [2022]AAPM Magnetic Resonance Task Group #9 on proton magnetic resonance spectroscopy (MRS) in the brain was formed to provide a reference document for acquiring and processing proton (1H) MRS acquired from brain tissue. MRS is becoming a common adjunct to magnetic resonance imaging (MRI), especially for the differential diagnosis of tumors in the brain. Even though MR imaging is an offshoot of MR spectroscopy, clinical medical physicists familiar with MRI may not be familiar with many of the common practical issues regarding MRS. Numerous research laboratories perform in vivo MRS on other magnetic nuclei, such as 31P, 13C, and 19F. However, most commercial MR scanners are generally only capable of spectroscopy using the signals from protons. Therefore this paper is of limited scope, giving an overview of technical issues that are important to clinical proton MRS, discussing some common clinical MRS problems, and suggesting how they might be resolved. Some fundamental issues covered in this paper are common to many forms of magnetic resonance spectroscopy and are written as an introduction for the reader to these methods. These topics include shimming, eddy currents, spatial localization, solvent saturation, and post-processing methods. The document also provides an extensive review of the literature to guide the practicing medical physicist to resources that may be useful for dealing with issues not covered in the current article.
[Proton magnetic resonance spectroscopy: a metabolic approach of cerebral tumors and their follow-up after external radiation therapy]. [2019]The same physical principles are the basis of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). Proton MRS is easily performed with clinical magnets (> or = 1.5 T) and may be added to routine MRI studies to provide metabolic information on pathological tissues. It represents an important tool to detect several metabolic compounds. The article will review the current status of proton MRS with a particular emphasis upon its clinical utility for the diagnosis of brain tumors and for the evaluation of the efficacy of radiotherapy.
Proton magnetic resonance spectroscopy: technique for the neuroradiologist. [2021]Magnetic resonance spectroscopy (MRS) provides information on neuronal and axonal viability, energetics of cellular structures, and status of cellular membranes. Proton MRS appeals to clinicians and scientists because its application in the clinical setting can increase the specificity of MR imaging. The objective of this article is to provide descriptive concepts of the technique and its application in vivo for a variety of patient populations. When appropriately incorporating MRS into the neuroradiologic evaluation, this technique produces relevant information to radiologists and clinicians for their understanding of adult and pediatric neurologically based disease processes.
In vivo Human MR Spectroscopy Using a Clinical Scanner: Development, Applications, and Future Prospects. [2022]MR spectroscopy (MRS) is a unique and useful method for noninvasively evaluating biochemical metabolism in human organs and tissues, but its clinical dissemination has been slow and often limited to specialized institutions or hospitals with experts in MRS technology. The number of 3-T clinical MR scanners is now increasing, representing a major opportunity to promote the use of clinical MRS. In this review, we summarize the theoretical background and basic knowledge required to understand the results obtained with MRS and introduce the general consensus on the clinical utility of proton MRS in routine clinical practice. In addition, we present updates to the consensus guidelines on proton MRS published by the members of a working committee of the Japan Society of Magnetic Resonance in Medicine in 2013. Recent research into multinuclear MRS equipped in clinical MR scanners is explained with an eye toward future development. This article seeks to provide an overview of the current status of clinical MRS and to promote the understanding of when it can be useful. In the coming years, MRS-mediated biochemical evaluation is expected to become available for even routine clinical practice.
Reproducibility of short echo time proton magnetic resonance spectroscopy using point-resolved spatially localized spectroscopy sequence in normal human brains. [2013]The reproducibility of short echo time proton MR spectroscopy (1H-MRS) in normal human brains was examined. Thirteen healthy volunteers were studied, and each underwent three MRS examinations. Second and third measurements were done on the same day, about two months after the first measurement, and interday and intraday reproducibility were evaluated. MRS was performed with proton brain examination/single voxel (PROBE/SV) and point-resolved spatially localized spectroscopy (PRESS) (repetition time = 2000 ms, echo time = 30 ms). Five metabolite ratios were computed; N-acetyl-aspartate (NAA)/creatine (Cr), choline (Cho)/Cr, myo-inositol (mI)/Cr, NAA/(NAA + Cr + Cho), and NAA/Cho. Their normal range and reproducibility were measured. For each metabolite ratio, there was no significant difference between interday difference and intraday difference, suggesting that the interval of two months has minimal effect on MRS measurements. MRS may be utilized for the observation of central nervous system diseases.
Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, Part I: Introduction to MRS. [2018]Magnetic resonance spectroscopy (MRS) provides a means to assess functional (metabolic activity) of the brain. It is now possible to perform MRS in a clinical setting with the use of an inexpensive software package called Proton Brain Exam/Single Voxel (PROBE/SV) developed by General Electric Medical System for use on their 1.5-T MR scanner. We have used PROBE for over a year and have found it to be useful in the evaluation of brain abnormalities. Most of our experience with MRS has been in the evaluation of children with brain tumors. In this first article of a two-part series, a simplified introduction to single-voxel MRS is presented, including: 1) the differences in the normal MRS spectra of the brains of infants, children, and adults demonstrating the variation in peaks of the common metabolities (N-acetylasparate, creatine, and choline); 2) the two types of MRS pulse sequences, stimulated echo acquisition mode (STEAM), a T1-weighted sequence, and point resolved spectroscopy (PRESS), a T2-weighted sequence; and 3) some of the factors that influence the production of diagnostic and nondiagnostic spectra. Part Two will report findings on the efficacy of MRS in children with brain tumors. With a basic understanding of MRS, the abnormal spectra in the diagnosis of brain tumors can be appreciated.